BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019;58:i43-54. [PMID: 30806709 DOI: 10.1093/rheumatology/key276] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 46.0] [Reference Citation Analysis]
Number Citing Articles
1 Marchiset A, Neuville M, Voiriot G, De Wolf J, Glorion M, Parquin F, Roux A, Guen ML, Allenbach Y, Zuber B, Cerf C; Foch Lung Transplant Group. High-Emergency Lung Transplantation for Interstitial Lung Disease Associated With Anti-MDA5 Dermatomyositis: A Case Report. Transplant Proc 2021;53:2613-5. [PMID: 34511249 DOI: 10.1016/j.transproceed.2021.08.012] [Reference Citation Analysis]
2 Guo X, Ji J, Zhang J, Hou X, Fu X, Luo Y, Mei Z, Feng Z. Anti-inflammatory and osteoprotective effects of Chikusetsusaponin Ⅳa on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine 2021;93:153801. [PMID: 34758437 DOI: 10.1016/j.phymed.2021.153801] [Reference Citation Analysis]
3 Patel DR, Urva S, Ho S, Buckman CJ, Ma Y, Lim J, Sissons SE, Zuniga MS, Philips D, Cox K, Dairaghi DJ. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects. Clin Transl Sci 2021;14:1037-48. [PMID: 33382916 DOI: 10.1111/cts.12968] [Reference Citation Analysis]
4 Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. Front Immunol 2020;11:1439. [PMID: 32655577 DOI: 10.3389/fimmu.2020.01439] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
5 Miller-Handley H, Luckett K, Govil A. Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Adv Chronic Kidney Dis 2020;27:434-41. [PMID: 33308510 DOI: 10.1053/j.ackd.2020.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Favoino E, Prete M, Catacchio G, Ruscitti P, Navarini L, Giacomelli R, Perosa F. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? Autoimmun Rev 2021;20:102750. [PMID: 33482338 DOI: 10.1016/j.autrev.2021.102750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
7 Wu JH, Imadojemu S, Caplan AS. The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy. Am J Clin Dermatol 2022. [PMID: 35583850 DOI: 10.1007/s40257-022-00693-0] [Reference Citation Analysis]
8 Nalairndran G, Chung I, Abdul Razack AH, Chung FF, Hii LW, Lim WM, Looi CK, Mai CW, Leong CO. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells. J Cell Mol Med 2021;25:8187-200. [PMID: 34322995 DOI: 10.1111/jcmm.16684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ciobanu DA, Poenariu IS, Crînguș LI, Vreju FA, Turcu-Stiolica A, Tica AA, Padureanu V, Dumitrascu RM, Banicioiu-Covei S, Dinescu SC, Boldeanu L, Siloși I, Ungureanu AM, Boldeanu MV, Osiac E, Barbulescu AL. JAK/STAT pathway in pathology of rheumatoid arthritis (Review). Exp Ther Med 2020;20:3498-503. [PMID: 32905201 DOI: 10.3892/etm.2020.8982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Reference Citation Analysis]
11 Mohamed MF, Klünder B, Othman AA. Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication. Clin Pharmacokinet 2020;59:531-44. [PMID: 31867699 DOI: 10.1007/s40262-019-00855-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Crowley JJ, Pariser DM, Yamauchi PS. A brief guide to pustular psoriasis for primary care providers. Postgrad Med 2021;133:330-44. [PMID: 33118424 DOI: 10.1080/00325481.2020.1831315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907-919. [PMID: 31486687 DOI: 10.1080/1744666x.2019.1648209] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
14 Wang S, Liu M, Li X, Zhang J, Wang F, Zhang C, Roden A, Ryu JH, Warrington KJ, Sun J, Matteson EL, Tschumperlin DJ, Vassallo R. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB J 2022;36:e22336. [PMID: 35522243 DOI: 10.1096/fj.202101436R] [Reference Citation Analysis]
15 van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, Van den Bosch F, Kim TH, Kishimoto M, Östör AJ, Combe B, Sui Y, Duan Y, Wung PK, Song IH. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open 2022;8:e002280. [PMID: 35896281 DOI: 10.1136/rmdopen-2022-002280] [Reference Citation Analysis]
16 Metcalfe RD, Putoczki TL, Griffin MDW. Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11. Front Immunol 2020;11:1424. [PMID: 32765502 DOI: 10.3389/fimmu.2020.01424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
17 Damerau A, Gaber T, Ohrndorf S, Hoff P. JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration. Int J Mol Sci 2020;21:E9004. [PMID: 33256266 DOI: 10.3390/ijms21239004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the Era of Targeted Therapies: Mapping the Road Ahead. Front Med (Lausanne) 2020;7:336. [PMID: 32974356 DOI: 10.3389/fmed.2020.00336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Hertzog J, Rehwinkel J. Regulation and inhibition of the DNA sensor cGAS. EMBO Rep 2020;21:e51345. [PMID: 33155371 DOI: 10.15252/embr.202051345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Worm M, Francuzik W, Kraft M, Alexiou A. Moderne Therapie der atopischen Dermatitis: Biologika und kleinmolekulare Medikamente. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2020;18:1085-93. [DOI: 10.1111/ddg.14175_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease. Kidney Int 2022:S0085-2538(22)00436-7. [PMID: 35661785 DOI: 10.1016/j.kint.2022.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. Pharmacotherapy. 2020;40:843-856. [PMID: 32542785 DOI: 10.1002/phar.2438] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
23 Zhu L, Cao Z, Wang S, Zhang C, Fang L, Ren Y, Xie B, Geng J, Xie S, Zhao L, Ma L, Dai H, Wang C. Single-Cell Transcriptomics Reveals Peripheral Immune Responses in Anti-Synthetase Syndrome-Associated Interstitial Lung Disease. Front Immunol 2022;13:804034. [PMID: 35250976 DOI: 10.3389/fimmu.2022.804034] [Reference Citation Analysis]
24 Dillon KL. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clin Cosmet Investig Dermatol 2021;14:691-714. [PMID: 34211288 DOI: 10.2147/CCID.S309215] [Reference Citation Analysis]
25 Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs 2020;25:89-100. [PMID: 32192366 DOI: 10.1080/14728214.2020.1745773] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
26 Swei EC, Fox CM, Bowles DW, Rizeq MN, Onyiah JC. Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera. ACG Case Rep J 2022;9:e00741. [PMID: 35018293 DOI: 10.14309/crj.0000000000000741] [Reference Citation Analysis]
27 Sperti M, Malavolta M, Ciniero G, Borrelli S, Cavaglià M, Muscat S, Tuszynski JA, Afeltra A, Margiotta DPE, Navarini L. JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies. Journal of Molecular Graphics and Modelling 2021;104:107789. [DOI: 10.1016/j.jmgm.2020.107789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gorantla S, Singhvi G, Rapalli VK, Waghule T, Dubey SK, Saha RN. Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status. Therapeutic Delivery 2020;11:269-84. [DOI: 10.4155/tde-2020-0029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
29 Liu X, Wu W, Fang L, Liu Y, Chen W. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. Front Immunol 2022;13:922782. [DOI: 10.3389/fimmu.2022.922782] [Reference Citation Analysis]
30 Kale SD, Mehrkens BN, Stegman MM, Kastelberg B, Carnes H, McNeill RJ, Rizzo A, Karyala SV, Coutermarsh-Ott S, Fretz JA, Sun Y, Koff JL, Rajagopalan G. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor. Front Immunol 2020;11:1311. [PMID: 32676080 DOI: 10.3389/fimmu.2020.01311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol 2020;31:100-4. [PMID: 32676567 DOI: 10.31138/mjr.31.1.100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int 2022;71:40-6. [PMID: 34815171 DOI: 10.1016/j.alit.2021.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
33 Sun L, Ouyang J, Zeng Z, Zeng C, Ma Y, Zeng F, Wu S. Targeted and activatable nanosystem for fluorescent and optoacoustic imaging of immune-mediated inflammatory diseases and therapy via inhibiting NF-κB/NLRP3 pathways. Bioact Mater 2022;10:79-92. [PMID: 34901531 DOI: 10.1016/j.bioactmat.2021.08.010] [Reference Citation Analysis]
34 Khalil BA, Shakartalla SB, Goel S, Madkhana B, Halwani R, Maghazachi AA, Alsafar H, Al-omari B, Al Bataineh MT. Immune Profiling of COVID-19 in Correlation with SARS and MERS. Viruses 2022;14:164. [DOI: 10.3390/v14010164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 2021;20:551-69. [PMID: 34002056 DOI: 10.1038/s41573-021-00195-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
36 Pleyer U, Neri P, Deuter C. New pharmacotherapy options for noninfectious posterior uveitis. Int Ophthalmol 2021;41:2265-81. [PMID: 33634341 DOI: 10.1007/s10792-021-01763-8] [Reference Citation Analysis]
37 Mueller AL, Payandeh Z, Mohammadkhani N, Mubarak SMH, Zakeri A, Alagheband Bahrami A, Brockmueller A, Shakibaei M. Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. Cells 2021;10:3017. [PMID: 34831240 DOI: 10.3390/cells10113017] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Liu R, Zhan S, Che Y, Shen J. Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases. J Med Chem 2021. [PMID: 34647463 DOI: 10.1021/acs.jmedchem.1c01186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Astrike-Davis EM, Coryell P, Loeser RF. Targeting cellular senescence as a novel treatment for osteoarthritis. Curr Opin Pharmacol 2022;64:102213. [PMID: 35447516 DOI: 10.1016/j.coph.2022.102213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Jadhav P, Jiang Y, Jarr K, Layton C, Ashouri JF, Sinha SR. Efficacy of Dietary Supplements in Inflammatory Bowel Disease and Related Autoimmune Diseases. Nutrients 2020;12:E2156. [PMID: 32698454 DOI: 10.3390/nu12072156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Ortega MA, García-montero C, Fraile-martinez O, Alvarez-mon MA, Gómez-lahoz AM, Lahera G, Monserrat J, Rodriguez-jimenez R, Quintero J, Álvarez-mon M. Immune-Mediated Diseases from the Point of View of Psychoneuroimmunoendocrinology. Biology 2022;11:973. [DOI: 10.3390/biology11070973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Smolen JS. Greetings from the editor 2020. Ann Rheum Dis 2019;79:1-2. [DOI: 10.1136/annrheumdis-2019-216758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
43 Morris G, Bortolasci CC, Puri BK, Marx W, O'Neil A, Athan E, Walder K, Berk M, Olive L, Carvalho AF, Maes M. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all? Cytokine 2021;144:155593. [PMID: 34074585 DOI: 10.1016/j.cyto.2021.155593] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
44 Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Front Immunol 2019;10:2342. [PMID: 31649667 DOI: 10.3389/fimmu.2019.02342] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 11.7] [Reference Citation Analysis]
45 Akpabio A, Adebajo A. Evaluating upadacitinib for the treatment of psoriatic arthritis. Expert Opin Pharmacother 2022;:1-5. [PMID: 35014922 DOI: 10.1080/14656566.2021.2006183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sun C, Xia J. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Med 2020;111:254-65. [PMID: 32166932 DOI: 10.23736/S0026-4806.20.06460-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Stellacci E, Moneta GM, Bruselles A, Barresi S, Pizzi S, Torre G, De Benedetti F, Tartaglia M, Insalaco A. The activating p.Ser466Arg change in STAT1 causes a peculiar phenotype with features of interferonopathies. Clin Genet 2019;96:585-9. [DOI: 10.1111/cge.13632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Minasyan M, Sharma L, Pivarnik T, Liu W, Adams T, Bermejo S, Peng X, Liu A, Ishikawa G, Perry C, Kaminski N, Gulati M, Herzog EL, Dela Cruz CS, Ryu C. Elevated IL-15 concentrations in the sarcoidosis lung are independent of granuloma burden and disease phenotypes. Am J Physiol Lung Cell Mol Physiol 2021;320:L1137-46. [PMID: 33851886 DOI: 10.1152/ajplung.00575.2020] [Reference Citation Analysis]
49 Tanimura S, Nakamura H, Horita T. Response to: 'Comment on 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara et al' by Rios Rodriguez et al. Ann Rheum Dis 2022;81:e94. [PMID: 32581087 DOI: 10.1136/annrheumdis-2020-218055] [Reference Citation Analysis]
50 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Clarke SLN, Ramanan AV. Tofacitinib in juvenile idiopathic arthritis. Lancet 2021;398:1943-5. [PMID: 34767763 DOI: 10.1016/S0140-6736(21)01444-6] [Reference Citation Analysis]
52 Lee J, Park Y, Jang SG, Hong SM, Song YS, Kim MJ, Baek S, Park SH, Kwok SK. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus. Front Immunol 2021;12:704526. [PMID: 34497607 DOI: 10.3389/fimmu.2021.704526] [Reference Citation Analysis]
53 Ll Wilkinson MG, Deakin CT, Papadopoulou C, Eleftheriou D, Wedderburn LR. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J 2021;19:146. [PMID: 34563217 DOI: 10.1186/s12969-021-00637-8] [Reference Citation Analysis]
54 Wittine K, Antolović R, Jelić D, Bracanović S, Cetina M, Andjelkovic U, Wittine O, Kraljević Pavelić S, Vinter A. Thienochromene derivatives inhibit pSTAT1 and pSTAT5 signaling induced by cytokines. Bioorg Med Chem Lett 2020;30:127415. [PMID: 32717616 DOI: 10.1016/j.bmcl.2020.127415] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care 2020;24:331. [PMID: 32527304 DOI: 10.1186/s13054-020-03020-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
56 Shams S, Martinez JM, Dawson JRD, Flores J, Gabriel M, Garcia G, Guevara A, Murray K, Pacifici N, Vargas MV, Voelker T, Hell JW, Ashouri JF. The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. Front Pharmacol 2021;12:680043. [PMID: 34122106 DOI: 10.3389/fphar.2021.680043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A. Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report. Ocul Immunol Inflamm 2022;:1-2. [PMID: 35587645 DOI: 10.1080/09273948.2022.2069128] [Reference Citation Analysis]
58 Agache I, Cojanu C, Laculiceanu A, Rogozea L. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. Allergy Asthma Immunol Res 2020;12:24-41. [PMID: 31743962 DOI: 10.4168/aair.2020.12.1.24] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
59 van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019;394:2108-17. [PMID: 31732180 DOI: 10.1016/S0140-6736(19)32534-6] [Cited by in Crossref: 61] [Cited by in F6Publishing: 21] [Article Influence: 20.3] [Reference Citation Analysis]
60 Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. Int J Mol Sci 2021;22:6211. [PMID: 34207510 DOI: 10.3390/ijms22126211] [Reference Citation Analysis]
61 Zhou Y, Wang P, Chen XY, Yan BX, Landeck L, Wang ZY, Xu F, Zheng M, Man XY. Sprouty1 exerts a preventive effect on the initiation of psoriasis by inhibiting innate immune antimicrobial peptide cathelicidin and immunocytes. Cell Prolif 2022;:e13290. [PMID: 35716036 DOI: 10.1111/cpr.13290] [Reference Citation Analysis]
62 Matucci A, Vivarelli E, Nencini F, Maggi E, Vultaggio A. Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors. Biomedicines 2021;9:1497. [PMID: 34680614 DOI: 10.3390/biomedicines9101497] [Reference Citation Analysis]
63 Low JT, Christie M, Ernst M, Dumoutier L, Preaudet A, Ni Y, Griffin MDW, Mielke LA, Strasser A, Putoczki TL, O'Reilly LA. Loss of NFKB1 Results in Expression of Tumor Necrosis Factor and Activation of Signal Transducer and Activator of Transcription 1 to Promote Gastric Tumorigenesis in Mice. Gastroenterology 2020;159:1444-1458.e15. [PMID: 32569771 DOI: 10.1053/j.gastro.2020.06.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Tsakali SS, Shanahan CM. Calcinosis: insights from other calcinoses. Curr Opin Rheumatol 2020;32:472-8. [PMID: 32890031 DOI: 10.1097/BOR.0000000000000746] [Reference Citation Analysis]
65 Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 2021;11:941-60. [PMID: 33996408 DOI: 10.1016/j.apsb.2020.12.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 28.0] [Reference Citation Analysis]
66 Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J 2021:ehab447. [PMID: 34343257 DOI: 10.1093/eurheartj/ehab447] [Reference Citation Analysis]
67 Papa R, Picco P, Gattorno M. The expanding pathways of autoinflammation: a lesson from the first 100 genes related to autoinflammatory manifestations. Adv Protein Chem Struct Biol 2020;120:1-44. [PMID: 32085880 DOI: 10.1016/bs.apcsb.2019.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
68 McInnes IB, Szekanecz Z, McGonagle D, Maksymowych WP, Pfeil A, Lippe R, Song IH, Lertratanakul A, Sornasse T, Biljan A, Deodhar A. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford) 2021:keab740. [PMID: 34668515 DOI: 10.1093/rheumatology/keab740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Cattalini M, Galli J, Zunica F, Ferraro RM, Carpanelli M, Orcesi S, Palumbo G, Pinelli L, Giliani S, Fazzi E, Badolato R. Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation. Front Pediatr 2021;9:725868. [PMID: 34778129 DOI: 10.3389/fped.2021.725868] [Reference Citation Analysis]
70 Ibrahim SSA, Salama MA, Selima E, Shehata RR. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways. Life Sci 2020;260:118261. [PMID: 32795539 DOI: 10.1016/j.lfs.2020.118261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
71 Kotyla PJ, Islam MA, Engelmann M. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis. Int J Mol Sci 2020;21:E7390. [PMID: 33036382 DOI: 10.3390/ijms21197390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
72 Wang F, Sun L, Wang S, Davis JM, Matteson EL, Murad MH, Luo F, Vassallo R. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Mayo Clinic Proceedings 2020;95:1404-19. [DOI: 10.1016/j.mayocp.2020.01.039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
73 Kim HO. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors. Arch Pharm Res 2020;43:1173-86. [PMID: 33161563 DOI: 10.1007/s12272-020-01282-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Kumar D, Trivedi N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomed Pharmacother 2021;139:111642. [PMID: 33940506 DOI: 10.1016/j.biopha.2021.111642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
75 Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev 2021;20:102902. [PMID: 34274542 DOI: 10.1016/j.autrev.2021.102902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Langan D, Rose NR, Moudgil KD. Common innate pathways to autoimmune disease. Clin Immunol 2020;212:108361. [PMID: 32058071 DOI: 10.1016/j.clim.2020.108361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cell Signal 2020;74:109721. [PMID: 32711111 DOI: 10.1016/j.cellsig.2020.109721] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 21.5] [Reference Citation Analysis]
78 Benanti G, Dagna L, Campochiaro C. Lights and shadows on JAK inhibitors for Ankylosing Spondylitis. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.018] [Reference Citation Analysis]
79 Moura RA, Fonseca JE. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. Front Med (Lausanne) 2020;7:607725. [PMID: 33614673 DOI: 10.3389/fmed.2020.607725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Guo P, Wang Z, Zhou Z, Tai Y, Zhang A, Wei W, Wang Q. Immuno-hippo: Research progress of the hippo pathway in autoimmune disease. Immunol Lett 2021;230:11-20. [PMID: 33345861 DOI: 10.1016/j.imlet.2020.12.006] [Reference Citation Analysis]
81 Liu X, Wang Z, Qian H, Tao W, Zhang Y, Hu C, Mao W, Guo Q. Natural medicines of targeted rheumatoid arthritis and its action mechanism. Front Immunol 2022;13:945129. [DOI: 10.3389/fimmu.2022.945129] [Reference Citation Analysis]
82 Jiang Y, Jarr K, Layton C, Gardner CD, Ashouri JF, Abreu MT, Sinha SR. Therapeutic Implications of Diet in Inflammatory Bowel Disease and Related Immune-Mediated Inflammatory Diseases. Nutrients 2021;13:890. [PMID: 33801883 DOI: 10.3390/nu13030890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Abboud R, Choi J, Ruminski P, Schroeder MA, Kim S, Abboud CN, DiPersio JF. Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease. Ther Adv Hematol 2020;11:2040620720914489. [PMID: 32537114 DOI: 10.1177/2040620720914489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
84 van Schaik TA, Chen KS, Shah K. Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy? Front Oncol 2021;11:678562. [PMID: 34141622 DOI: 10.3389/fonc.2021.678562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Bayat M, Asemani Y, Mohammadi MR, Sanaei M, Namvarpour M, Eftekhari R. An overview of some potential immunotherapeutic options against COVID-19. Int Immunopharmacol 2021;95:107516. [PMID: 33765610 DOI: 10.1016/j.intimp.2021.107516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Hong SM, Lee J, Jang SG, Lee J, Cho ML, Kwok SK, Park SH. Type I Interferon Increases Inflammasomes Associated Pyroptosis in the Salivary Glands of Patients with Primary Sjögren's Syndrome. Immune Netw 2020;20:e39. [PMID: 33163247 DOI: 10.4110/in.2020.20.e39] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Liu J, Hou Y, Sun L, Li C, Li L, Zhao Y, Zeng X, Zhang F, Zheng W. A pilot study of tofacitinib for refractory Behçet's syndrome. Ann Rheum Dis 2020;79:1517-20. [PMID: 32461206 DOI: 10.1136/annrheumdis-2020-217307] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
88 Gorantla S, Saha RN, Singhvi G. Design of experiment-driven stability-indicating RP-HPLC method for the determination of tofacitinib in nanoparticles and skin matrix. Futur J Pharm Sci 2021;7. [DOI: 10.1186/s43094-021-00325-0] [Reference Citation Analysis]
89 Lopatina E, Marshall DA, Coupal L, Le Lorier J, Choquette D. Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis. Curr Med Res Opin 2021;37:157-66. [PMID: 33136462 DOI: 10.1080/03007995.2020.1846172] [Reference Citation Analysis]
90 Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 2020;50:620-32. [PMID: 32299202 DOI: 10.3906/sag-2004-168] [Cited by in Crossref: 169] [Cited by in F6Publishing: 152] [Article Influence: 84.5] [Reference Citation Analysis]
91 Mura E, Masnada S, Antonello C, Parazzini C, Izzo G, Garau J, Sproviero D, Cereda C, Orcesi S, Veggiotti P, Zuccotti G, Dilillo D, Penagini F, Tonduti D. Ruxolitinib in Aicardi-Goutières syndrome. Metab Brain Dis 2021;36:859-63. [PMID: 33721182 DOI: 10.1007/s11011-021-00716-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Worm M, Francuzik W, Kraft M, Alexiou A. Modern therapies in atopic dermatitis: biologics and small molecule drugs. J Dtsch Dermatol Ges 2020;18:1085-92. [PMID: 32666644 DOI: 10.1111/ddg.14175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
93 Fan Y, Hao YJ, Zhang ZL. Systemic lupus erythematosus: year in review 2019. Chin Med J (Engl) 2020;133:2189-96. [PMID: 32810049 DOI: 10.1097/CM9.0000000000000983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus - past imperfect, future tense. Nat Rev Rheumatol. 2019;15:403-412. [PMID: 31165780 DOI: 10.1038/s41584-019-0235-5] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 27.0] [Reference Citation Analysis]
95 Nasonov EL, Lila AM. BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES. Naučno-praktičeskaâ revmatologiâ 2020;58:304-16. [DOI: 10.14412/1995-4484-2020-304-316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
96 Talotta R. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease. Immunotherapy 2021;13:241-56. [PMID: 33410346 DOI: 10.2217/imt-2020-0270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
97 Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli R. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020;111:102468. [PMID: 32317220 DOI: 10.1016/j.jaut.2020.102468] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 30.5] [Reference Citation Analysis]
98 Alves C, Penedones A, Mendes D, Batel-Marques F. Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. BMJ Open 2020;10:e041420. [PMID: 33384392 DOI: 10.1136/bmjopen-2020-041420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Menshawey R, Menshawey E, Alserr AHK, Abdelmassih AF. JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations. Cardiovasc Endocrinol Metab 2021;10:80-8. [PMID: 34109302 DOI: 10.1097/XCE.0000000000000237] [Reference Citation Analysis]
100 Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules 2020;25:E3321. [PMID: 32707925 DOI: 10.3390/molecules25153321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
101 Murakami M, Kamimura D, Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity 2019;50:812-31. [DOI: 10.1016/j.immuni.2019.03.027] [Cited by in Crossref: 127] [Cited by in F6Publishing: 125] [Article Influence: 42.3] [Reference Citation Analysis]
102 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Reference Citation Analysis]
103 Vyas SP, Hansda AK, Goswami R. Rheumatoid arthritis: ‘melting pot’ of T helper subsets. International Reviews of Immunology 2019;38:212-31. [DOI: 10.1080/08830185.2019.1621865] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
104 Elkoshi Z. The Binary Classification of Protein Kinases. J Inflamm Res 2021;14:929-47. [PMID: 33776467 DOI: 10.2147/JIR.S303750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Parra-Izquierdo I, Sánchez-Bayuela T, Castaños-Mollor I, López J, Gómez C, San Román JA, Sánchez Crespo M, García-Rodríguez C. Clinically used JAK inhibitor blunts dsRNA-induced inflammation and calcification in aortic valve interstitial cells. FEBS J 2021. [PMID: 34009721 DOI: 10.1111/febs.16026] [Reference Citation Analysis]
106 Jiang J, Zhao M, Chang C, Wu H, Lu Q. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. Clin Rev Allergy Immunol 2020;59:248-72. [PMID: 32557263 DOI: 10.1007/s12016-020-08798-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
107 Wang W, Bhattacharyya S, Marangoni RG, Carns M, Dennis-aren K, Yeldandi A, Wei J, Varga J. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. Journal of Scleroderma and Related Disorders 2020;5:40-50. [DOI: 10.1177/2397198319865367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
108 Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). Int J Mol Med. 2021;47. [PMID: 33655327 DOI: 10.3892/ijmm.2021.4847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol 2020;235:5903-24. [DOI: 10.1002/jcp.29593] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
110 Huarte E, O'Connor RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, Yang YO, Truong L, Huang T, Naim A, Milone MC, Smith PA. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clin Cancer Res 2020;26:6299-309. [PMID: 32998963 DOI: 10.1158/1078-0432.CCR-20-1739] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
111 Ni Y, Low JT, Silke J, O'Reilly LA. Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. Front Immunol 2022;13:835997. [PMID: 35844493 DOI: 10.3389/fimmu.2022.835997] [Reference Citation Analysis]
112 Parra-Izquierdo I, Melrose AR, Pang J, Lakshmanan HHS, Reitsma SE, Vavilapalli SH, Larson MK, Shatzel JJ, McCarty OJT, Aslan JE. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. Platelets 2021;:1-12. [PMID: 34097573 DOI: 10.1080/09537104.2021.1934665] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Zimmerman DH, Mikecz K, Markovics A, Carambula RE, Ciemielewski JC, Toth DM, Glant TT, Rosenthal KS. Vaccination by Two DerG LEAPS Conjugates Incorporating Distinct Proteoglycan (PG, Aggrecan) Epitopes Provides Therapy by Different Immune Mechanisms in a Mouse Model of Rheumatoid Arthritis. Vaccines (Basel) 2021;9:448. [PMID: 34063326 DOI: 10.3390/vaccines9050448] [Reference Citation Analysis]
114 George G, Shyni GL, Raghu KG. Current and novel therapeutic targets in the treatment of rheumatoid arthritis. Inflammopharmacology 2020;28:1457-76. [PMID: 32948901 DOI: 10.1007/s10787-020-00757-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
115 Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology (Oxford) 2020;59:iv79-89. [PMID: 33053192 DOI: 10.1093/rheumatology/keaa435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
116 Mohamed MF, Beck D, Camp HS, Othman AA. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. J Clin Pharmacol 2020;60:188-97. [PMID: 31448433 DOI: 10.1002/jcph.1513] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
117 Narla S, Silverberg JI. The suitability of treating atopic dermatitis with Janus kinase inhibitors. Expert Rev Clin Immunol 2022. [PMID: 35377276 DOI: 10.1080/1744666X.2022.2060822] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Cacciapaglia F, Perniola S, Urso L, Fornaro M, Iannone F. Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients. Rheumatology (Oxford) 2020;59:1442-4. [PMID: 31899517 DOI: 10.1093/rheumatology/kez652] [Reference Citation Analysis]
119 Słuczanowska-Głąbowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J Clin Med 2021;10:4307. [PMID: 34640327 DOI: 10.3390/jcm10194307] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Alim K, Bruyère A, Lescoat A, Jouan E, Lecureur V, Le Vée M, Fardel O. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Expert Opin Drug Metab Toxicol 2021;17:259-71. [PMID: 33292029 DOI: 10.1080/17425255.2021.1862084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
121 Byrne EM, Llorián-Salvador M, Lyons TJ, Chen M, Xu H. Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes. Int J Mol Sci 2021;22:11876. [PMID: 34769307 DOI: 10.3390/ijms222111876] [Reference Citation Analysis]
122 Labib BA, Chigbu DI. Therapeutic Targets in Allergic Conjunctivitis. Pharmaceuticals 2022;15:547. [DOI: 10.3390/ph15050547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Gotthardt D, Trifinopoulos J, Sexl V, Putz EM. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. Front Immunol 2019;10:2590. [PMID: 31781102 DOI: 10.3389/fimmu.2019.02590] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
124 Choe J, Kim S. Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks. Medicina 2022;58:426. [DOI: 10.3390/medicina58030426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 2020;12:1759720X20930116. [PMID: 32612710 DOI: 10.1177/1759720X20930116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
126 Candon S, Rammaert B, Foray AP, Moreira B, Gallego Hernanz MP, Chatenoud L, Lortholary O. Chronic Disseminated Candidiasis During Hematological Malignancies: An Immune Reconstitution Inflammatory Syndrome With Expansion of Pathogen-Specific T Helper Type 1 Cells. J Infect Dis 2020;221:1907-16. [PMID: 31879764 DOI: 10.1093/infdis/jiz688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]